Artificial Macrocycles as IL-17A/IL-17RA Antagonists

Area of Science:

• Immunology
• Biochemistry
• Drug Discovery

Background:

• Interleukin 17(A) (IL17A) is a pro-inflammatory cytokine implicated in autoimmune and inflammatory conditions.
• Current IL17A antagonists, primarily monoclonal antibodies (mAbs), have demonstrated clinical efficacy.
• Targeting protein-protein interactions (PPIs) remains a challenge in drug development.

Purpose of the Study:

• To evaluate the potential of artificial macrocycles as novel antagonists for the IL17A-IL17R pathway.
• To elucidate the biological activity and structure-activity relationships (SAR) of these macrocycles.
• To assess the macrocycles' ability to compete with mAbs for challenging targets like PPIs.

Main Methods:

• Co-crystal structure analysis of IL17A-IL17R interactions with macrocycles.
• Assessment of biological activity and binding affinity of macrocyclic antagonists.
• Comparative analysis of macrocycles versus monoclonal antibodies in inhibiting IL17A-IL17R interaction.

Main Results:

• Recently designed artificial macrocycles exhibit potent antagonism against IL17A and IL17R.
• Co-crystal structures provide insights into the mechanism of action and SAR of macrocycles.
• Macrocycles demonstrate the capacity to compete with mAbs for complex targets, including PPIs.

Conclusions:

• Artificial macrocycles represent a promising new class of therapeutics for IL17A-mediated inflammatory diseases.
• Understanding macrocycle SAR through structural biology can guide the development of more effective antagonists.
• Macrocycles offer a viable alternative to mAbs for targeting difficult protein-protein interactions.